NGEN.F Stock Overview
Engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
NervGen Pharma Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.79 |
| 52 Week High | CA$2.99 |
| 52 Week Low | CA$1.16 |
| Beta | 1.35 |
| 11 Month Change | 11.63% |
| 3 Month Change | -11.39% |
| 1 Year Change | 26.06% |
| 33 Year Change | -15.94% |
| 5 Year Change | 67.29% |
| Change since IPO | 37.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| NGEN.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 15.5% | -3.8% | -1.0% |
| 1Y | 26.1% | 9.8% | 30.3% |
Return vs Industry: NGEN.F exceeded the US Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: NGEN.F underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| NGEN.F volatility | |
|---|---|
| NGEN.F Average Weekly Movement | 10.4% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NGEN.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NGEN.F's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Mike Kelly | www.nervgen.com |
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer’s disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage.
NervGen Pharma Corp. Fundamentals Summary
| NGEN.F fundamental statistics | |
|---|---|
| Market cap | US$112.67m |
| Earnings (TTM) | -US$17.19m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.4x
P/E RatioIs NGEN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGEN.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$24.01m |
| Earnings | -CA$24.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NGEN.F perform over the long term?
See historical performance and comparison